

REVIEW ARTICLE

Ketamine Therapy in Psychiatry: A Comprehensive Review

Asif Khan¹, Satyaveer², Shrikant K. Nair³, Deepali Gaikwad Joseph⁴

HOW TO CITE THIS ARTICLE:

Asif Khan, Satyaveer, Shrikant K. Nair, Deepali Gaikwad Joseph. Ketamine Therapy in Psychiatry: A Comprehensive Review. J Psychiatr Nurs. 2025; 14(2): 70–74.

ABSTRACT

Ketamine, traditionally known as an anesthetic agent, has garnered attention for its rapid acting antidepressant properties, particularly in patients with treatment resistant depression (TRD). The compound's unique pharmacological profile primarily as an NMDA receptor antagonist has enabled its repositioning in psychiatric settings, where conventional antidepressants often fall short. This review delves into the evolving role of ketamine in psychiatry, examining its mechanisms of action, therapeutic applications, clinical efficacy, safety concerns, and emerging trends in the field. While ketamine therapy offers promise, its use raises ethical, regulatory, and long-term safety considerations that require continued research and careful implementation.

KEYWORDS

• Ketamine • Psychiatry • Depression • NMDA receptor • Antidepressant
• Treatment-resistant depression • Mental health • Suicidality • Glutamatergic system • Neuroplasticity

INTRODUCTION

Mental health disorders, especially major depressive disorder (MDD), have a profound impact on individuals and societies worldwide. Approximately 30% of individuals with MDD do not respond adequately to traditional antidepressant treatments, thereby falling into the category of treatment-resistant

depression (TRD)¹. The urgent need for innovative therapeutic options has prompted exploration into unconventional agents such as ketamine; a dissociative anesthetic with rapid antidepressant properties.

Ketamine's psychiatric applications mark a paradigm shift in treating mood disorders, offering symptom relief within hours

AUTHOR'S AFFILIATION:

¹ Faculty, College of Nursing, All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India.

² Faculty, College of Nursing, All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India.

³ Faculty, College of Nursing, All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India.

⁴ Faculty, College of Nursing, All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India.

CORRESPONDING AUTHOR:

Asif Khan, Faculty, College of Nursing, All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India.

E-mail: akp.akbnz@gmail.com

➤ Received: 01-05-2025 ➤ Accepted: 13-05-2025



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (<https://www.rfppl.co.in>)

rather than weeks, as seen with selective serotonin reuptake inhibitors (SSRIs). Initially developed as a phencyclidine derivative, ketamine's journey from battlefield anesthetic to psychiatric tool underscores the evolving understanding of depression's neurobiology².

Aspect	Ketamine Therapy	Traditional Antidepressants
Mechanism of Action	NMDA receptor antagonist; enhances glutamate transmission and synaptic plasticity.	Primarily monoamine-based (e.g., SSRIs, SNRIs) enhancing serotonin, norepinephrine.
Onset of Action	Rapid (within hours to 24 hours).	Delayed (2 to 6 weeks).
Duration of Effect	Short-acting; may require repeated infusions for sustained effect.	Long-lasting with regular use.
Efficacy in TRD*	High efficacy in treatment-resistant depression (TRD).	Lower response in TRD cases.
Use in Suicidal Ideation	Proven rapid reduction in suicidal thoughts.	Limited short-term efficacy in acute suicidality.
Administration Route	IV, intranasal (esketamine), or oral (less common).	Oral (tablets or capsules).
FDA Approval	Esketamine (Spravato) approved for TRD and suicidal depression.	Many approved antidepressants for MDD, anxiety disorders.
Side Effects	Dissociation, dizziness, elevated blood pressure, nausea.	Sexual dysfunction, weight gain, GI disturbances, insomnia.
Addiction Potential	Moderate (especially with misuse or non-medical use).	Low addiction potential.
Monitoring Needs	Requires in-clinic administration and monitoring post-dose.	Less intensive monitoring; outpatient basis.
Cost and Accessibility	Expensive; limited to specialized clinics.	Widely available and more affordable.
Therapeutic Use Beyond MDD	PTSD, OCD, bipolar depression (off-label).	Broad use in MDD, GAD, panic disorder, OCD, etc.

Pharmacology of Ketamine

Chemical Composition and Isomers:

Ketamine is a racemic mixture comprising two enantiomers: S-(+)-ketamine and R-(-)-ketamine. The S-isomer, esketamine, is more

potent in anesthetic and antidepressant effects, leading to its approval for psychiatric use in intranasal form³.

Mechanism of Action

The primary mechanism through which ketamine exerts its antidepressant effects is antagonism of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor⁴. This antagonism leads to increased synaptic glutamate release, activating AMPA receptors, which subsequently trigger downstream signaling pathways like BDNF (brain-derived neurotrophic factor) and mTOR (mammalian target of rapamycin), enhancing synaptogenesis and neuroplasticity⁵.

Additionally, ketamine influences opioid receptors, dopamine systems, and inflammatory pathways, contributing to its multifaceted psychiatric effects⁶.

Therapeutic Applications

Major Depressive Disorder (MDD):

Numerous clinical trials have validated ketamine's efficacy in alleviating depressive symptoms in MDD, especially among patients with TRD. A single intravenous infusion of ketamine has shown significant mood improvements within hours, with effects lasting up to one week⁷.

Suicidal Ideation:

Ketamine demonstrates rapid reduction of suicidal thoughts, making it a potentially life-saving intervention in acute settings. Studies report substantial decreases in suicidality within 24 hours post-infusion⁸. The rapid onset is crucial, especially during psychiatric emergencies.

Bipolar Depression:

While initial studies cautioned against ketamine use in bipolar disorder due to risk of mania, subsequent trials have shown it to be effective in the depressive phase, provided mood stabilizers accompany its use⁹.

Post-Traumatic Stress Disorder (PTSD):

Emerging evidence suggests ketamine may benefit individuals with PTSD. Its role in reducing trauma-related memories and improving mood has been explored in both military and civilian populations¹⁰.

Obsessive-Compulsive Disorder (OCD):

Pilot studies have indicated short-term symptom relief in OCD patients following ketamine infusion, although results are less robust than those for depression¹¹.

Administration Routes and Dosage

Intravenous (IV) Infusion:

The most studied and widely used method is IV infusion, typically at a subanesthetic dose of 0.5 mg/kg over 40 minutes¹². This route offers controlled administration and reliable absorption.

Intranasal Esketamine:

Approved by the FDA in 2019, intranasal esketamine (Spravato) is used in conjunction with oral antidepressants for TRD. It provides a more convenient alternative but necessitates in-clinic administration due to potential side effects¹³.

Oral, Sublingual, and Intramuscular Routes:

Other routes such as oral, sublingual, or intramuscular (IM) are under investigation for homebased or broader applications, though bioavailability and consistency pose challenges¹⁴.

Efficacy and Clinical Outcomes

Onset and Duration:

Unlike traditional antidepressants, ketamine acts within hours, offering quick symptom relief. However, effects are transient, often peaking within 24–48 hours and waning by 7–10 days, necessitating maintenance dosing¹⁵.

Response Rates:

Studies report response rates of 50–70% in TRD patients following ketamine therapy, a marked improvement over conventional antidepressants in this group¹⁶.

Comparative Efficacy:

Head-to-head trials comparing ketamine with ECT, SSRIs, and transcranial magnetic stimulation (TMS) suggest ketamine is non-inferior and, in many cases, preferred due to faster onset¹⁷.

Safety and Side Effects

Acute Side Effects:

1. Common side effects include dissociation, euphoria, elevated blood pressure, nausea,

and dizziness. These typically resolve within hours post-administration¹⁸.

Cognitive Effects:

Concerns about cognitive impairment, particularly with long-term use, remain under investigation. Some studies report transient memory deficits, while others find no significant impact¹⁹.

Addiction and Abuse Potential:

Ketamine's history as a recreational drug ("Special K") raises fears about addiction and misuse. However, when used in clinical settings under supervision, abuse risk is minimal²⁰.

Bladder Toxicity:

Prolonged high-dose exposure may cause ulcerative cystitis, though rare in therapeutic psychiatric use²¹.

Ethical and Regulatory Considerations

Off-label Use:

Much of ketamine's psychiatric application remains off-label, leading to variability in treatment protocols and legal oversight²².

Access and Cost:

High costs, lack of insurance coverage, and limited certified clinics restrict patient access. The need for monitored administration adds logistical burdens²³.

Consent and Vulnerable Populations:

Due to its dissociative effects, informed consent is critical. Use in adolescents, elderly, and pregnant women is not yet well-established and should be approached cautiously²⁴.

Ketamine Clinics and Integration into Practice

The rise of ketamine infusion clinics across North America, Europe, and Australia has expanded access but introduced concerns regarding standardization, clinical oversight, and profit-driven models²⁵.

Integration into mainstream psychiatry requires collaboration across disciplines, including psychopharmacology, nursing, and psychotherapy.

Future Directions and Research

Biomarkers for Response:

Ongoing research seeks to identify biomarkers

that predict treatment response, such as EEG patterns, inflammatory markers, or genetic polymorphisms²⁶.

Long-Term Safety Studies:

Longitudinal studies are necessary to evaluate neurocognitive outcomes, bladder health, and addiction risk associated with long-term ketamine therapy²⁷.

Combination Therapies:

Ketamine may enhance outcomes when combined with CBT, mindfulness training, or other psychotropics, leveraging its neuroplasticity-promoting effects²⁸.

Psychedelic Adjuncts:

Interest is growing in pairing ketamine with psychedelic-assisted psychotherapy, viewing the dissociative state as a therapeutic window for deep psychological processing²⁹.

Role of the Nurse in Ketamine Therapy

Nurses play a vital role in the safe administration of ketamine therapy. They are responsible for pre-treatment assessment, monitoring vital signs, and ensuring patient safety during and after infusion. Nurses assess for dissociative symptoms, blood pressure changes, and psychological reactions, providing both emotional support and medical intervention if needed³⁰. They also educate patients about the procedure, possible side effects, and post-treatment care³¹. Furthermore, nurses contribute to documentation, observe for adverse effects, and report to the psychiatrist or prescribing physician, making them essential to integrated care delivery in ketamine clinics³².

CONCLUSION

Ketamine therapy represents one of the most transformative developments in modern psychiatry. Its rapid onset and efficacy in treatment-resistant cases offer hope for many patients who previously had limited options. While its long-term safety and ideal delivery models are still being refined, ketamine's potential is undeniable. With rigorous research, ethical implementation, and patient-centered care, ketamine can become a cornerstone in the evolving psychiatric landscape.

REFERENCES

1. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., *et al.* Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*. 2006; 163(11): 1905–17.
2. Domino E.F. Taming the ketamine tiger. *Anesthesiology*. 2010;113(3):678–84.
3. Paul R., Schaaff N., Padberg F., Möller H.J., Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. *CNS Drugs*. 2009;23(12):1057–61.
4. Zarate C.A. Jr, Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., *et al.* A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch Gen Psychiatry*. 2006; 63(8): 856–64.
5. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. *Science*. 2012;338(6103):68–72.
6. Williams N.R., Schatzberg A.F. NMDA antagonist treatment of depression. *CNS Drugs*. 2016; 30(1): 33–44.
7. Berman R.M., Cappiello A, Anand A., Oren D.A., Heninger G.R., Charney D.S., *et al.* Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry*. 2000;47(4):351–4.
8. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. *Am J Psychiatry*. 2009;166(4):459–65.
9. Diazgranados N., Ibrahim L., Brutsche NE, Newberg A., Kronstein P., Khalife S., *et al.* Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. *Bipolar Disord*. 2010; 12(6): 702–3.
10. Feder A., Parides M.K., Murrough J.W., Perez A.M., Morgan J.E., Saxena S., *et al.* Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. *JAMA Psychiatry*. 2014; 71(6): 681–8.
11. Rodriguez C.I., Kegeles L.S., Levinson A, Feng T., Marcus S.M., Vermes D., *et al.* Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-

- concept. *J Clin Psychiatry*. 2013; 74(9): e982–90.
12. Short B., Fong J., Galvez V., Shelker W., Loo C.K. Side-effects associated with ketamine use in depression: a systematic review. *J Affect Disord*. 2018; 227: 576–82.
 13. U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. *FDA News Release*. 2019 [cited 2025 May 2]. Available from: <https://www.fda.gov/news-events/press-announcements>
 14. Sakurai H., Gamo N.J., Kolb H., Mattis J., Egervari G., Needham M., *et al*. Long-lasting efficacy of low-dose oral ketamine for depression in a patient with treatment-resistant bipolar disorder. *J Psychopharmacol*. 2020; 34(1): 109–12.
 15. Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., *et al*. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. *Am J Psychiatry*. 2013; 170(10): 1134–42.
 16. Coyle C.M., Laws K.R. The use of ketamine as an antidepressant: a systematic review and meta-analysis. *J Psychopharmacol*. 2015; 29(4): 289–99.
 17. Wilkinson S.T., Toprak M., Turner M.S., Levine S.P., Katz R.B., Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. *Am J Psychiatry*. 2017; 174(7): 695–6.
 18. Ballard E.D., Wills K., Lally N., Luckenbaugh D.A., Richards E.M., Machado-Vieira R., *et al*. Anhedonia as a clinical correlate of suicidal thoughts in major depressive disorder. *J Affect Disord*. 2017; 210: 42–9.
 19. Morgan C.J., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. *Addiction*. 2010; 105(1): 121–33.
 20. Bonnet U. Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine's antidepressant response and the development of ketamine addiction. *CNS Neurosci Ther*. 2015; 21(2): 188–90.
 21. Shahani R., Streutker C., Dickson B., Stewart R.J. Ketamine-associated ulcerative cystitis: a new clinical entity. *BJU Int*. 2007; 100(6): 1141–3.
 22. Sanacora G., Frye M.A., McDonald W., Mathew S.J., Turner M.S., Schatzberg A.F., *et al*. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry*. 2017; 74(4): 399–405.
 23. Schatzberg A.F. A word to the wise about ketamine. *Am J Psychiatry*. 2014; 171(3): 262–4.
 24. Loo C.K., Galvez V., O'Keefe E., Mitchell P.B., Hadzi-Pavlovic D., Leyden J., *et al*. Placebo-controlled pilot trial testing ketamine augmentation of ECT for depression. *World J Biol Psychiatry*. 2016; 17(1): 47–54.
 25. Andrade C. Ketamine for depression, 2: diagnostic and contextual indications. *J Clin Psychiatry*. 2017; 78(2): e150–3.
 26. Duman R.S., Li N., Liu R.J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. *Neuropharmacology*. 2012; 62(1): 35–41.
 27. Daly E.J., Singh J.B., Fedgchin M., Cooper K., Lim P., Shelton R.C., *et al*. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. *JAMA Psychiatry*. 2018; 75(2): 139–48.
 28. Wilkinson S.T., Farmer C., Ballard E.D., Mathew S.J., Grunebaum M.F., Murrough J.W., *et al*. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. *Psychother Psychosom*. 2018; 87(1): 22–31.
 29. Yaden D.B., Griffiths R.R. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. *JAMA Psychiatry*. 2020; 77(9): 787–8.
 30. Sanacora G., Frye M.A., McDonald W., Mathew S.J., Turner M.S., Schatzberg A.F., *et al*. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry*. 2017; 74(4): 399–405.
 31. Wilkinson S.T., Toprak M., Turner M.S., Levine S.P., Katz R.B., Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. *Am J Psychiatry*. 2017; 174(7): 695–6.
 32. Short B., Fong J., Galvez V., Shelker W., Loo C.K. Side-effects associated with ketamine use in depression: a systematic review. *J Affect Disord*. 2018; 227: 576–82.